AMANDA EVANS: Open Payments
NPI 1154752780 · GREER, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,192 in 82 payments from 21 companies in 2025. Trend: 2023 $1,152 · 2024 $1,300 · 2025 $1,192
Food & beverage: $1,192
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 19 | $174 |
| ABBVIE INC. | 16 | $173 |
| Novo Nordisk Inc | 10 | $160 |
| AstraZeneca Pharmaceuticals LP | 6 | $157 |
| PFIZER INC. | 5 | $91 |
| Axsome Therapeutics, Inc. | 4 | $84 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $65 |
| Astellas Pharma US Inc | 2 | $53 |
| GlaxoSmithKline, LLC. | 2 | $30 |
| Amgen Inc. | 2 | $30 |
Products named: JARDIANCE, MOUNJARO, FARXIGA, AIRSUPRA, UBRELVY, Auvelity, VRAYLAR, Ozempic.
Industry payments across SC — which companies pay providers there.
